A Temasek-backed Chinese genomics firm has kicked off its latest fundraising round with a target of up to $200 million, drawing interest from investors including Hillhouse Capital Group and Sequoia Capital China, two people with direct knowledge of the matter said.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
